| Literature DB >> 26696967 |
Elvira Marín1, Claudia M Parra-Giraldo1, Carolina Hernández-Haro1, María L Hernáez2, César Nombela3, Lucía Monteoliva3, Concha Gil4.
Abstract
Candida albicans is a human opportunistic fungus and it is responsible for a wide variety of infections, either superficial or systemic. C. albicans is a polymorphic fungus and its ability to switch between yeast and hyphae is essential for its virulence. Once C. albicans obtains access to the human body, the host serum constitutes a complex environment of interaction with C. albicans cell surface in bloodstream. To draw a comprehensive picture of this relevant step in host-pathogen interaction during invasive candidiasis, we have optimized a gel-free shaving proteomic strategy to identify both, human serum proteins coating C. albicans cells and fungi surface proteins simultaneously. This approach was carried out with normal serum (NS) and heat inactivated serum (HIS). We identified 214 human and 372 C. albicans unique proteins. Proteins identified in C. albicans included 147 which were described as located at the cell surface and 52 that were described as immunogenic. Interestingly, among these C. albicans proteins, we identified 23 GPI-anchored proteins, Gpd2 and Pra1, which are involved in complement system evasion and 7 other proteins that are able to attach plasminogen to C. albicans surface (Adh1, Eno1, Fba1, Pgk1, Tdh3, Tef1, and Tsa1). Furthermore, 12 proteins identified at the C. albicans hyphae surface induced with 10% human serum were not detected in other hypha-induced conditions. The most abundant human proteins identified are involved in complement and coagulation pathways. Remarkably, with this strategy, all main proteins belonging to complement cascades were identified on the C. albicans surface. Moreover, we identified immunoglobulins, cytoskeletal proteins, metabolic proteins such as apolipoproteins and others. Additionally, we identified more inhibitors of complement and coagulation pathways, some of them serpin proteins (serine protease inhibitors), in HIS vs. NS. On the other hand, we detected a higher amount of C3 at the C. albicans surface in NS than in HIS, as validated by immunofluorescence.Entities:
Keywords: Candida albicans; GPI-anchored proteins; coagulation pathways; complement pathways; host-pathogen interaction; human serum; shaving; surface proteins
Year: 2015 PMID: 26696967 PMCID: PMC4672057 DOI: 10.3389/fmicb.2015.01343
Source DB: PubMed Journal: Front Microbiol ISSN: 1664-302X Impact factor: 5.640
Selected .
| GPI-anchored proteins | 11 | 12 | – | 23 |
| – | ||||
| Proteins involved in cell wall organization or biogenesis | 8 | 18 | – | 26 |
| Act1, Bmh1, Gda1, Msb2, | Agm1, | – | ||
| Cell surface proteins | 40 | 21 | 1 | 62 |
| Ape2, | Cht3 | |||
| Plasma membrane proteins | 8 | 28 | – | 36 |
| Ahp1, Orf19.6553, Cof1, Met15, Pfy1, | – | |||
| Others immunogenic proteins | 6 | 2 | – | 8 |
| – | ||||
| 155 |
The classification is hierarchical and exclusive. Proteins were included if they were detected in at least two replicates of one condition with at least 2 peptides in one replicate. There are four replicates of Normal Serum (NS) and three replicates of Heat Inactivated Serum (HIS). Protein names from Candida Genome Database (CGD) (Inglis et al., 2012).
GPI-cell wall proteins reviewed in De Groot et al. (2003), Pardo et al. (2004), Chaffin (2008), Klis et al. (2009).
Gene Ontology (GO) terms (in parentheses the GO identifier) at CGD.
Proteins able to induce human serum antibodies in patients with invasive candidiasis are indicated in bold (Pitarch et al., 2004, 2006, 2008, 2011; Mochon et al., 2010).
Human proteins of complement and coagulation pathways identified on the surface of .
| P01023 | A2M | Alpha-2-macroglobulin | 2 (15,11) | 3 (10,9,70) |
| C4BPA | C4b-binding protein alpha chain | 4 (5,3,4,9) | 3 (15,8,4) | |
| C4BPB | C4b-binding protein beta chain | 1 (2) | 2 (2,3) | |
| Clusterin | Extracellular chaperone or ApoJ | 4 (11,8,13,19) | 3 (11,13,18) | |
| COLEC11 | Collectin kidney protein 1 or collectin-11 | 4 (5,5,2,4) | 0 | |
| C1qA | Complement C1q subcomponent subunit A | 0 | 2 (1,4) | |
| C1qB | Complement C1q subcomponent subunit B | 3 (1,1,1) | 3 (5,5,4) | |
| C1qC | Complement C1q subcomponent subunit C | 3 (1,1,2) | 3 (7,5,6) | |
| C1r | Complement C1r subcomponent | 2 (2,7) | 3 (21,15,14) | |
| C1r-like | Complement C1r-like protein | 0 | 3 (6,5,5) | |
| C1s | Complement C1s subcomponent | 2 (1,10) | 3 (23,14,11) | |
| C2 | Complement component C2 | 1 (2) | 3 (19,15,10) | |
| C3 | Complement component C3 | 4 (103,106,141,147) | 3 (141,105,138) | |
| C4-A | Complement component C4-A | 4 (32,32,94,98) | 3 (90,61,76) | |
| C4-B | Complement component C4-B | 4 (32,33,95,98) | 2 (90,62) | |
| C5 | Complement component C5 | 3 (34,23,21) | 3 (68,46,70) | |
| C6 | Complement component C6 | 3 (20,18,4) | 3 (21,14,16) | |
| C7 | Complement component C7 | 4 (13,9,8,6) | 3 (6,11,16) | |
| C8-A | Complement component C8 alpha chain | 4 (13,11,6,7) | 3 (11,8,8) | |
| C8-B | Complement component C8 beta chain | 4 (5,6,16,27) | 3 (22,16,13) | |
| C8-G | Complement component C8 gamma chain | 4 (6,6,4,1) | 3 (6,4,9) | |
| C9 | Complement component C9 | 4 (17,15,17,22) | 3 (24,17,14) | |
| FB | Complement factor B | 4 (8,3,8,10) | 3 (47,31,28) | |
| FD | Complement factor D | 0 | 3 (2,2,4) | |
| FH | Complement factor H | 2 (5,3) | 3 (18,17,13) | |
| FI | Complement factor I | 1 (1) | 3 (3,3,6) | |
| FP | Complement factor P or Properdin | 4 (5,5,2,2) | 1 (3) | |
| Ficolin-2 | Collagen/fibrinogen domain containing protein 2 | 0 | 2 (1,3) | |
| Ficolin-3 | Collagen/fibrinogen domain containing protein 3 | 1 (1) | 3 (5,2,7) | |
| MASP2 | Mannan-binding lectin serine protease 2 | 3 (2,2,5) | 1 (3) | |
| GPLD1 | Phosphatidylinositol-glycan-specific phospholipase D | 0 | 2 (4,15) | |
| C1INH | Plasma protease C1 inhibitor (Serpin G1) | 0 | 3 (20,14,24) | |
| VTN | Vitronectin or protein S | 4 (10,12,10,11) | 3 (14,11,13) | |
| SERPINA1 | Alpha-1-antitrypsin (AAT) | 4 (4,3,6,12) | 3 (37,35,47) | |
| SERPINF2 | Alpha-2-antiplasmin | 4 (2,2,9,13) | 3 (17,16,18) | |
| SERPINC1 | Antithrombin-III (AT-III) | 4 (2,2,5,10) | 3 (13,16,25) | |
| ApoH | Beta-2-glycoprotein 1; APC inhibitor; Apolipoprotein H | 2 (1,1) | 3 (8,3,4) | |
| CPB2 | Carboxypeptidase B2; Thrombin-activable fibrinolysis inhibitor | 4 (2,1,12,10) | 3 (5,3,3) | |
| F9 | Coagulation factor IX | 4 (3,2,3,5) | 3 (5,4,4) | |
| F5 | Coagulation factor V | 4 (8,2,11,22) | 3 (11,4,8) | |
| F7 | Coagulation factor VII | 2 (2,3) | 2 (3,2) | |
| F10 | Coagulation factor X | 2 (2,2) | 3 (6,6,6) | |
| F12 | Coagulation factor XII | 1 (1) | 2 (4,8) | |
| F13A | Coagulation factor XIII A chain | 3 (1,2,1) | 2 (4,7) | |
| F13B | Coagulation factor XIII B chain | 0 | 3 (2,1,2) | |
| FGA | Fibrinogen alpha chain | 4 (13,12,3,7) | 3 (6,6,10) | |
| FGB | Fibrinogen beta chain | 4 (13,10,1,7) | 3 (6,11,14) | |
| FGG | Fibrinogen gamma chain | 3 (6,6,4) | 3 (2,5,10) | |
| FN1 | Fibronectin; Binds cell surfaces and various compounds (collagen, fibrin, heparin…) | 4 (60,62,15,16) | 3 (29,38,24) | |
| HBB | Hemoglobin subunit beta | 4 (7,9,3,10) | 3 (9,7,11) | |
| HPA | Heparanase | 2 (1,3) | 0 | |
| HCF2 | Heparin cofactor 2 (Serpin D1) | 4 (8,11,34,28) | 3 (29,23,27) | |
| HRG | Histidine-rich glycoprotein | 4 (22,23,26,23) | 3 (21,24,17) | |
| HABP2 | Hyaluronan-binding protein 2 | 0 | 3 (4,3,5) | |
| KNG1 | Kininogen-1 | 4 (6,2,11,15) | 3 (11,14,11) | |
| KLKB1 | Plasma kallikrein | 4 (7,8,2,1) | 3 (8,9,10) | |
| SERPINA5 | Plasma serine protease inhibitor | 0 | 2 (3,6) | |
| PLG | Plasminogen | 4 (5,6,21,34) | 3 (41,41,15) | |
| GP5 | Platelet glycoprotein V | 2 (2,2) | 3 (5,2,3) | |
| SERPINA10 | Protein Z-dependent protease inhibitor | 4 (1,1,10,9) | 3 (6,5,7) | |
| F2 | Prothrombin | 4 (16,18,17,25) | 3 (21,17,10) | |
| PROC | Vitamin K-dependent protein C | 1 (3) | 2 (3,4) | |
| PROS1 | Vitamin K-dependent protein S | 3 (1,1,11) | 3 (6,3,14) | |
| VWF | von Willebrand factor | 4 (18,16,19,72) | 3 (52,36,9) | |
Accession number, gene symbol and function from UniProtKB/Swiss-Prot database (Uniprot, 2014).
Proteins were included if they were identified in at least two replicates of one condition with at least 2 peptides in one replicate.
Figure 1Percentage representation of human protein groups identified in normal serum (NS) and heat inactivated serum (HIS) samples by shaving . Overall, 171 proteins were identified in both conditions and were classified into the complement pathway, coagulation pathway, metabolism, immunoglobulin, cytoskeleton, and others.
Comparison of complement proteins identified on the cell surface of .
| Lectin pathway | 7 proteins | 7 proteins |
| MASP2 | ||
| Classical pathway | 8 proteins | 10 proteins |
| C1qB, C1qC, C1r, C1s, C2 | ||
| Alternative pathway | 3 proteins | 4 proteins |
| C3, FB, FP | C3, FB, | |
| Membrane attack complex (MAC) | 7 proteins | 7 proteins |
| C5, C6, C7, C8-A, C8-B, C8-G, C9 | C5, C6, C7, C8-A, C8-B, C8-G, C9 | |
| Complement inhibitors | 7 proteins | 9 proteins |
| A2M, C4BPA, C4BPB | A2M, |
Proteins indicated in bold are only identified in one condition.
Proteins with
are identified only in one replicate of the indicated condition.
Identified proteins belonging to the SERPIN family.
| SERPINA1 | Alpha 1-antitrypsin | Human neutrophil elastase | 4 (4,3,6,12) | 3 (37,35,47) | |
| SERPINA3 | Alpha 1-antichymotrypsin | Cathepsin G | 2 (1,2) | 3 (27,19,30) | |
| SERPINA4 | Kallistatin | Kallikrein | 2 (5,10) | 3 (13,19,16) | |
| SERPINA5 | Plasma serine protease inhibitor | Protein C | 0 | 2 (3,6) | |
| SERPINA6 | Cortisol-binding globulin | Non-inhibitory; cortisol binding | 0 | 3 (11,8,12) | |
| SERPINA7 | Thyroxine-binding globulin | Non-inhibitory; thyroxine binding | 2 (2,1) | 3 (6,4,14) | |
| SERPINA8 | Angiotensionogen | Non-inhibitory; Precursor of angiotensin I | 4 (6,5,5,5) | 3 (11,13,19) | |
| SERPINA10 | Protein Z-related protease inhibitor | Factor Z and XI | 4 (1,1,10,9) | 3 (6,5,7) | |
| SERPINC1 | Antithrombin-III | Thrombin and factors IXa, Xa, and XIa | 4 (2,2,5,10) | 3 (13,16,25) | |
| SERPIND1 | Heparin cofactor II | Thrombin | 4 (8,11,34,28) | 3 (29,23,27) | |
| SERPINF1 | Pigment epithelium derived factor | Non-inhibitory; Potent anti-angiogenic molecule | 1 (1) | 3 (11,10,19) | |
| SERPINF2 | Alpha 2-antiplasmin | Plasmin and trypsin | 4 (2,2,9,13) | 3 (17,16,18) | |
| SERPING1 | Plasma protease C1 inhibitor | C1r, C1s, F12a, kallikrein, F11a, plasmin, MASP1, MASP2 | 0 | 3 (20,14,24) | |
Figure 2Protein ranking of complement and coagulation proteins identified on normal serum (NS) and heat inactivated serum (HIS) samples according to the average of NSAF. C. albicans was incubated with 10% human serum at 37°C (normal serum-NS or heat inactivated serum-HIS) and NSAF was calculated for proteins belonging to complement and coagulation proteins. The proteins were ordered according to their NSAF obtained in NS samples, from more to less abundant. Gradient color ranges from red (more abundant) to green (less abundant).
Analysis of peptides corresponding to cleavage fragments produced during complement activation and to contact regions in MAC formation.
| C2b | 0 | 0 | 4 | 4 |
| C3a | 8 | 2 | 10 | 3 |
| C4a | 5 | 1 | 4 | 1 |
| C5a | 0 | 0 | 5 | 5 |
| Ba | 1 | 0 | 5 | 4 |
| C6-MACPF | 13 | 0 | 19 | 6 |
| C7-MACPF | 4 | 0 | 15 | 12 |
| C8-A-MACPF | 4 | 0 | 8 | 4 |
| C8-B-MACPF | 19 | 1 | 19 | 0 |
Identified peptides belong to the indicated released region or remain part of the full-length protein.
Gray background highlights identification in HIS condition.
Figure 3Detection of C3 and factor B on Immunofluorescence assay to detect C3 and factor B (FB) on C. albicans surface incubated 30 min, 1.5 and 5 h with normal serum (NS; left panels) or heat inactivated serum (HIS; right panels). Control images showed the background of secondary antibody (anti-rabbit-A488). (B) Co-localization of C3 and FB with C. albicans plasmatic membrane (staining with PKH26) was examined by the analysis of confocal microscopy images, after 5 h of incubation with NS and HIS. Representative images are shown. Yellow arrows indicate position of transversal sections of illustrative histograms. Co-localization analysis was performed using FiJi software. Red staining of plasmatic membrane was done with PKH26, blue staining of DNA with DAPI and green staining with anti-rabbit-A488. Line in bottom right corner indicated in all figures corresponds to a 5 μm.
Figure 4Model of interactions among proteins of the complement pathways identified on . Proteins identified in normal serum (NS) samples in (A,B). Proteins belonging to lectin and classical pathways are represented in (A) and to alternative pathway in (B). Proteins mainly identified on heat inactivated serum (HIS) in (C). Identified proteins on samples are indicated with gray background and not-identified in white. Complement fragments released during complement activation are indicated with triangles. Peptides belonging to complement fragments that can be released or be part of a full-length protein are indicated with *. Numbers in (A,B) correspond to sequential steps during complement pathways activation. (A) Collectin-11 was only identified in NS samples. MASP2 was identified in NS and MASP1 was not identified in any sample. Fc (constant region of Ig) of IgGs or IgMs start classical complement pathway. (B) Properdin was identified in NS and Factor D (FD) was not. (C) Ficolin-2, Ficolin-3, C1qA, C1INH, and FD were identified only in HIS samples. C1INH dissociates the C1qrs complex, blocks alternative C3 convertase and inhibits C3 activation by kallikrein. C2 was identified in HIS, including 4 peptides of C2b. Five peptides belonging to FBa were identified in HIS condition. Signally, peptides belonging to C5a fragment were only identified in HIS samples.